Nurix Therapeutics Presents at Baird Global Healthcare Conference 2025
ByAinvest
Thursday, Sep 11, 2025 7:23 am ET1min read
NRIX--
During the presentation, Arthur Sands, the CEO, President, and Director of Nurix Therapeutics, highlighted the company's strategic priorities. Sands noted that the company is about to enter pivotal studies in chronic lymphocytic leukemia (CLL) as their primary program, which includes the highly selective BTK degrader, NX-5948, now known as bexobrutideg or Bexdeg. The company is actively planning Phase II and III programs for this drug, with recent disclosures on the design considerations for the Phase III study [2].
Additionally, Sands mentioned other degraders in the pipeline, such as NX-2127, which targets BTK and transcription factors IKZF1 and IKZF3, and NX-1607, an inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B). These drugs are in various stages of development, including preclinical and partnered drug discovery pipelines [1].
The presentation underscored Nurix Therapeutics' commitment to advancing innovative therapies and its robust pipeline of targeted protein degradation medicines. The company's strategic focus on CLL and other cancer types positions it as a key player in the biopharmaceutical industry.
The presentation at the Baird Global Healthcare Conference 2025 provided investors and financial professionals with an update on the company's progress and future plans, reinforcing its potential in the biopharmaceutical sector.
Nurix Therapeutics presents at Baird Global Healthcare Conference 2025. Brian Skorney, a senior biotech analyst, leads the presentation. Details of the presentation are not specified.
On September 10, 2025, Nurix Therapeutics, Inc. (NASDAQ: NRIX) presented at the Baird Global Healthcare Conference. Brian Skorney, a senior biotech analyst, led the presentation. The company is focused on the discovery, development, and commercialization of targeted protein degradation medicines aimed at improving treatment options for patients with cancer and inflammatory diseases [1].During the presentation, Arthur Sands, the CEO, President, and Director of Nurix Therapeutics, highlighted the company's strategic priorities. Sands noted that the company is about to enter pivotal studies in chronic lymphocytic leukemia (CLL) as their primary program, which includes the highly selective BTK degrader, NX-5948, now known as bexobrutideg or Bexdeg. The company is actively planning Phase II and III programs for this drug, with recent disclosures on the design considerations for the Phase III study [2].
Additionally, Sands mentioned other degraders in the pipeline, such as NX-2127, which targets BTK and transcription factors IKZF1 and IKZF3, and NX-1607, an inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B). These drugs are in various stages of development, including preclinical and partnered drug discovery pipelines [1].
The presentation underscored Nurix Therapeutics' commitment to advancing innovative therapies and its robust pipeline of targeted protein degradation medicines. The company's strategic focus on CLL and other cancer types positions it as a key player in the biopharmaceutical industry.
The presentation at the Baird Global Healthcare Conference 2025 provided investors and financial professionals with an update on the company's progress and future plans, reinforcing its potential in the biopharmaceutical sector.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet